The Hematologic Malignancy Center at Dana-Farber Boston Children's Cancer and Blood Disorders Center is one of the top pediatric leukemia and lymphoma treatment centers in the world. In addition to treating lymphomas and leukemias, our Center treats the primary types of histiocytosis, a condition that shares some of the characteristics of cancer and is often treated by using some of the same therapies.
Highlights of the Hematologic Malignancy Center include:
Read our Insight blog for information and inspiration about Dana-Farber/Boston Children's treatment and research for pediatric blood cancers.
Specialists in our Lymphoma Treatment Program, part of the Hematologic Malignancy Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, have deep experience in diagnosing and treating a wide range of newly diagnosed and relapsed lymphomas.
Lymphomas that we treat include:
Learn more about our Lymphoma Treatment Program.
The Hematologic Malignancy Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center is home to one of the top leukemia treatment programs in the world. Our program has played a leading role in refining treatment for childhood leukemia, resulting in cure rates of more than 90 percent for acute lymphoblastic leukemia (ALL). We continue to lead clinical trials designed to increase cure rates, decrease treatment-related side effects, and improve care for long-term survivors.
Leukemias that we treat include:
Learn more about our Leukemia Treatment Program.
Dana-Farber/Boston Children's Cancer and Blood Disorders Center provides expert treatment for newly diagnosed or recurrent histiocytosis, which is a cancer-like condition and may involve treatment with chemotherapy.
Our doctors are experts in the diagnosis and treatment of the major types of histiocytosis and related disorders, including:
Learn more about our Histiocytosis Treatment Program.
Our Node Assessment Program (NAP) provides a multidisciplinary approach to the care of children with persistent swelling of the lymph nodes (or glands), a condition known as lymphadenopathy. Pediatric patients of all ages have access to expert clinicians that include otolaryngologists, surgeons, pathologists, hematologists/oncologists, infectious disease specialists and radiologists. The first of its kind in New England, the Node Assessment Program accepts referrals, second opinions, and consultations for children with lymphadenopathy that require further evaluation to establish cause, severity, and treatment.
Learn more about our Node Assessment Program.
Browse clinical trials
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: